桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-025 桂林莱茵生物科技股份有限公司 关于召开 2024 年度股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 4、会议召开的日期、时间： （1）现场会议的召开时间：2025 年 4 月 18 日下午 15:00； （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为 2025 年 4 月 18 日上午 9:15—9：25，9：30—11:30 以及下午 13:00—15:00；通过深圳证券 交易所互联网投票系统（http://wltp.cninfo.com.cn）投票时间为 2025 年 4 月 18 日上午 9:15 至下午 15:00。 5、会议召开方式：本次股东会采取现场表决与网络投票相结合的方式。 2025 年 3 月 26 日，桂林莱茵生物科技股份有限公司（以下简称"公司"） 第七届董事会第四次会议审议通过了《关于召开 2024 年度股东会的议案》，现 将本次股东会的有关事项公告如下： 一、召开会议的基本情况 1、会议届次：2024 年度 ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-019 桂林莱茵生物科技股份有限公司（以下简称"公司"）关于召开公司第七届 监事会第三次会议的通知于 2025 年 3 月 16 日以短信、即时通讯工具及电子邮件 的方式发出，会议于 2025 年 3 月 26 日上午 11:00 在公司四楼会议室以现场结合 通讯的方式召开。会议应亲自出席监事 3 人，实亲自出席监事 3 人，全体高管列 席了会议，会议由监事会主席李元元先生主持，会议的召开符合《中华人民共和 国公司法》（以下简称"公司法"）和《公司章程》的规定，会议合法有效。 二、监事会会议审议情况 经认真的讨论和审议，会议以记名投票方式表决，形成决议如下： 1、会议以 3 票同意、0 票反对、0 票弃权审议通过《2024 年度监事会工作 报告》；[该议案需提交 2024 年度股东会审议] 《2024 年度监事会工作报告》同日刊登于巨潮资讯网（www.cninfo.com.cn）。 2、会议以 3 票同意、0 票反对、0 票弃权审议通过《2024 年度报告全文及 摘要》；[该议案需提交 2024 年度股东会审议] 经 ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-018 桂林莱茵生物科技股份有限公司 第七届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 桂林莱茵生物科技股份有限公司（以下简称"公司"）关于召开第七届董事 会第四次会议的通知于 2025 年 3 月 16 日以短信、即时通讯工具及电子邮件的方 式发出，会议于 2025 年 3 月 26 日上午 10：00 在公司四楼会议室以现场结合通讯 的方式召开。本次会议应参与表决董事 7 名，实参与表决董事 7 名，公司全体监 事、高级管理人员列席了会议。会议由董事长谢永富先生主持，会议的召开符合 《中华人民共和国公司法》（以下简称"公司法"）和《公司章程》的有关规定， 会议合法有效。 二、董事会会议审议情况 经充分的讨论和审议，会议以记名投票方式表决，形成如下决议： 1、会议以 7 票同意、0 票反对、0 票弃权审议通过《2024 年度总经理工作报 告》； 与会董事认真听取了公司总经理谢永富先生代表公司经营管理层所作的 20 ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,771,759,914.59, representing an 18.60% increase compared to ¥1,493,929,546.69 in 2023[6]. - The net profit attributable to shareholders for 2024 was ¥163,008,773.57, a significant increase of 97.56% from ¥82,510,982.99 in 2023[6]. - The net profit after deducting non-recurring gains and losses surged by 634.19% to ¥151,358,130.25 in 2024 from ¥20,615,597.65 in 2023[6]. - The net cash flow from operating activities improved by 36.99% to ¥159,713,597.04 in 2024, compared to ¥116,589,971.61 in 2023[6]. - The total assets at the end of 2024 were ¥5,018,729,917.67, an 8.50% increase from ¥4,625,577,132.96 at the end of 2023[6]. - The company reported a basic earnings per share of ¥0.22 for 2024, doubling from ¥0.11 in 2023[6]. - The company achieved total revenue of 1,771.76 million yuan in 2024, representing a year-on-year growth of 18.60%[73]. - The net profit attributable to shareholders reached 163.01 million yuan, with a significant year-on-year increase of 97.56%[73]. Market Trends and Industry Outlook - The company anticipates continued growth in the plant extract industry, with global market sales projected to reach $18.49 billion in 2024, driven by increasing consumer preference for natural products[28]. - The plant extract industry in China is experiencing a shift towards customized services, driven by increasing consumer demand for personalized plant extract formulations[32]. - In 2024, China's export value of plant extracts is projected to reach $3.01 billion, maintaining a leading position in the global market[37]. - The U.S., Japan, and India are the top three export markets for Chinese plant extracts, with exports to the U.S. accounting for 22.3% of the total[37]. - The global market for functional foods is projected to reach $155.5 billion by 2024, driven by increasing consumer demand for natural and healthy products[54]. - The natural sweetener market is experiencing significant growth driven by global "sugar reduction" trends and safety concerns over artificial sweeteners, with 108 countries implementing sugar taxes by 2024[56]. - The global health industry is projected to grow significantly, with China's life and health industry reaching 10 trillion yuan in 2023, reflecting a compound annual growth rate of 7% from 2018 to 2023[138]. Product Development and Innovation - The company has obtained 170 patents, including breakthroughs in the full synthesis technology of monk fruit glycosides, driving the industry towards higher value-added products[43]. - The company has initiated mass production of rare high-value steviol glycosides and has developed a full synthesis technology for monk fruit sweeteners, which could revolutionize the industry[52]. - The company is developing new products, including a synthetic monk fruit sweetener and a new steviol glycoside, which are expected to enhance market competitiveness[100]. - The company is focusing on new product development, particularly in the area of steviol glycosides, which is expected to enhance its market position[181]. - The company aims to accelerate the development of 3-5 new products in the synthetic biology sector, with a focus on commercializing the full synthesis technology of monk fruit sweetener V within the year[160]. Strategic Initiatives and Expansion - The company is focused on expanding its market presence and enhancing product offerings in response to the growing demand for health-oriented products[28]. - The company has established a global strategic layout with three production bases, four marketing centers, and five R&D centers, enhancing its competitive edge in the plant extract industry[42]. - The company is expanding its global supply chain, exploring opportunities in Southeast Asia, South America, and Africa to enhance risk management and support rapid business expansion[66]. - The company plans to enhance its global supply chain system to meet the increasing demand for supply chain diversity, particularly in key markets for natural sweeteners[134]. - The company is focusing on market expansion strategies to increase its share in the health product sector[122]. Governance and Compliance - The company has implemented a comprehensive governance structure, ensuring compliance with relevant laws and regulations, enhancing transparency and accountability[184]. - The company’s board of directors consists of 7 members, including 3 independent directors, ensuring a balanced governance framework[185]. - The company has committed to timely and accurate information disclosure, utilizing multiple platforms to ensure equal access for all shareholders[186]. - The company has established a crisis management protocol to address potential operational disruptions effectively[188]. - The company maintains complete asset independence from its controlling shareholders, with no assets or funds being occupied by them[186]. Financial Management and Risk Control - The company emphasizes the importance of financial management to minimize risks related to accounts receivable and inventory impairment[175]. - The company plans to establish a risk warning mechanism by 2025, covering risk identification, assessment, and management processes to better respond to market, policy, and industry risks[163]. - The company is implementing a multi-level talent training system to improve employees' professional knowledge and management capabilities[177]. - The company is focusing on enhancing its R&D capabilities to address the challenges of homogenized competition in the plant extraction industry, aiming to transition from traditional raw material suppliers to comprehensive service providers[144]. Sustainability and Environmental Initiatives - The company targets to achieve a "zero-carbon benchmark park" by 2025 through initiatives like photovoltaic power projects and waste recycling, aiming for full clean energy supply at its core production base[166]. - The company is committed to building a trust-based brand through technological innovation and quality service, transitioning from a raw material supplier to a product service provider[161]. - The company is focusing on sustainability initiatives, aiming to reduce operational costs by 10% through energy efficiency measures[192]. Shareholder Engagement and Communication - The company has established a complete organizational structure, with independent operational management and no overlap with controlling shareholders[187]. - The annual shareholders' meeting had a participation rate of 43.14%[189]. - The company is actively engaging with investors to discuss its 2024 performance outlook and strategies for natural sweetener procurement and sales price changes[178].

桂林莱茵生物科技股份有限公司 2024年度利润分配方案 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、审议程序 桂林莱茵生物科技股份有限公司（以下简称"公司"）于 2025 年 3 月 26 日召开第七届董事会第四次会议、第七届监事会第三次会议，审议通过了《2024 年度利润分配方案》，该议案尚需提交公司 2024 年度股东会审议。 二、2024 年度利润分配方案的基本情况 桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-020 （一）2024 年度利润分配方案的具体内容 根据致同会计师事务所（特殊普通合伙）出具的审计报告，2024 年度公司 实现归属于上市公司股东的净利润 163,008,773.57 元，根据《中华人民共和国公 司法》和《公司章程》的有关规定提取 10%法定盈余公积金 24,549,746.82 元， 2024 年初公司合并报表未分配利润 802,643,591.83 元，2024 年末公司合并报表 口径可供股东分配利润为 794,416,887.78 元（每 10 股未分配利润 10.9 ...

莱茵生物 20250307 2025-03-07 摘要 • 莱茵生物以罗汉果和银杏叶提取物起家，通过 FDA 的 GRAS 认证和与嘉 华股份的甜菊糖协议，奠定了国际市场基础。2018 年第四代天然甜味剂 基地投产，并与竞争对手签订独家分销合同，2019 年进军工业大麻， 2022 年正式量产。 • 公司在天然甜味剂领域占据市场份额，受益于全球天然气危机，预计未来 五年复合增长率达 13%。通过自建工厂和并购拓展产能，新产能逐步投产， 满足未来需求。工业大麻领域，受美国农业法案影响，供过于求，公司寻 求电子烟文化突破，目标 2025-2026 年盈亏平衡。 • 莱茵生物构建了全产业链布局，从采购端的"公司+合作社+农户"模式， 到原料端的规模化种植和成本控制，再到产品端与国际香精香料龙头企业 合作，以及自建工厂和并购，均展现出显著优势，新工厂投产将进一步释 放产能。 • 近期增长点包括新产能落地、合成生物项目量产（如 TAJRM 系列提高田野 菊提取物产量）以及工业大麻雾化项目。签订三年项目协议，目标 2025- 2026 年工业大麻业务盈亏平衡，共同推动公司增长。 Q&A 莱茵生物的市场地位和发展历程是怎样 ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-016 桂林莱茵生物科技股份有限公司 第七届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 桂林莱茵生物科技股份有限公司（以下简称"公司"）关于召开第七届董事 会第三次会议的通知于 2025 年 2 月 26 日以短信、即时通讯工具及电子邮件的方 式发出，会议于 2025 年 2 月 28 日下午 15：00 以通讯方式召开。本次会议应参与 表决董事 7 名，实参与表决董事 7 名，公司全体监事、高级管理人员列席了会议。 公司董事长谢永富先生主持本次会议，会议的召开符合《公司法》和《公司章程》 的有关规定，会议合法有效。 二、董事会会议审议情况 经充分的讨论和审议，会议以记名投票方式表决，形成如下决议： 1、会议以 7 票同意、0 票反对、0 票弃权审议通过《关于聘任郑辉女士为公 司副总经理的议案》；[简历附后] 第七届董事会第三次会议决议。 特此公告。 桂林莱茵生物科技股份有限公司董事会 二〇二五年三月一日 经总经理 ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-015 桂林莱茵生物科技股份有限公司 关于为控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外担保进展情况概述 （一）本次对外担保情况 近日，桂林莱茵生物科技股份有限公司（以下简称"公司"）与成都农村商 业银行股份有限公司蒲江支行（以下简称"成都农商行蒲江支行"）签订了《最 高额保证合同》，为公司控股子公司成都华高生物制品有限公司（以下简称"华 高生物"）向成都农商行蒲江支行申请的人民币5,500万元综合授信提供了连带 责任保证担保。同时，公司控股子公司华高生物的其他股东按出资比例向公司提 供反担保。 额度范围内。 二、被担保人基本情况 1、公司名称：成都华高生物制品有限公司 2、成立日期：2007年3月6日 3、注册地点：成都市蒲江县寿安镇迎宾大道628号 4、法定代表人：顾峰 （二）对外担保审议情况 公司于2024年4月9日召开第六届董事会第三十一次会议，审议通过了《关于 2024年度为子公司提供担保额度预计的议案》，同意公司为 ...

Core Insights - The company, Rhine Biotech, has received FDA GRAS certification for its Rebaudioside M2 (RebM2), allowing it to be used as a food additive and dietary supplement in the U.S. market [1][2] - RebM2 is a rare, high-value steviol glycoside with superior sweetness characteristics, better taste purity, stability, and solubility compared to other sweeteners like RebD and RebM [1] - The enzymatic conversion method used by the company significantly improves the efficiency, cost, and quality of RebM2 production, addressing market demand for high-performance sweeteners [1] Production and Market Impact - The company's synthetic biology workshop is set to begin operations in September 2024, enabling mass production of RebM2 [2] - The FDA certification will facilitate the global promotion and sales of RebM2, with expected accelerated capacity release from the synthetic biology workshop [2] - The company plans to focus on deep development of RebM2, emphasizing application innovation and research to enhance its product matrix and service innovation capabilities [2] Competitive Advantage - The FDA GRAS certification signifies that the product has passed stringent safety and quality assessments, meeting the entry requirements for the U.S. food and beverage market [2] - This certification is expected to enhance the company's competitive edge and overall strength in the market, positively impacting future development [2]

证券时报网讯，莱茵生物(002166)2月16日晚间公告，近日，公司收到美国食品药品监督管理局 （FDA）的认证通知，公司酶转甜菊糖苷RebM2正式通过GRAS（一般认为安全的英文缩写，Generally Recognized as Safe）认证，可作为食品添加剂、膳食补充剂使用，标志着该产品具备进入美国食品、饮 料市场的准入条件。 ...